#Correction
Corrects an earlier piece or a popular misconception. Stays on the record.
PT-141 for male ED: what the FDA says
PT-141 is FDA-approved for low sexual desire in premenopausal women, not male erectile dysfunction, and the off-label male use has far thinner evidence.
Orzeyful isn't Ozempic for the brain
The FDA approved oveporexton for narcolepsy in August 2026. It targets the neuropeptide orexin, but the drug itself is not a peptide like semaglutide.
Browse other coverage
Latest from the blog
GLP-1s and shoulder replacement safety
A claims-database study found more 90-day readmissions among non-diabetic GLP-1 users after shoulder replacement, but it cannot establish cause.
Iran's GLP-1 Cost-Effectiveness Model
An Iranian 68-week model found semaglutide cost-effective at its threshold, while tirzepatide offered more benefit at a higher estimated cost.
Semaglutide and Handgrip Strength
A new systematic review found very low-certainty evidence on handgrip strength after semaglutide, not proof of strength preservation or loss.
How Oral Semaglutide Enhancers Differ
A preclinical comparison of SNAC, DDM and LLC found distinct intestinal transport and barrier-response patterns for semaglutide.
TAB trial: tirzepatide plus buprenorphine
The recruiting TAB trial will test tirzepatide added to buprenorphine for opioid use disorder, but its design paper reports no outcomes.
Tirzepatide and Lithium: A New Case Report
A newly indexed case report links tirzepatide and lithium toxicity, but its accessible record contains no clinical details or evidence of causation.